All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
Muna QayedDuring the 2021 TCT Meetings Digital Experience, the GvHD Hub spoke to Muna Qayed, Winship Cancer Institute of Emory University, Atlanta, US. We asked, In what setting is abatacept most effective as GvHD prophylaxis?
In what setting is abatacept most effective as GvHD prophylaxis?
In this video, Qayed discusses a multicenter phase II trial that looks at the addition of abatacept to standard GvHD prophylaxis in patients with hematological malignancies undergoing transplantation. Qayed believes abatacept could significantly open up the donor pool for patients who don't have a well-matched donor in the registry.
Your opinion matters
When would you be most likely to consider prescribing belumosudil third-line and beyond?